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Abstract The fully human anti-lipopolysaccharide (LPS) im-
munoglobulin M (IgM) monoclonal antibody panobacumab
was developed as an adjunctive immunotherapy for the treat-
ment of O11 serotype Pseudomonas aeruginosa infections.
We evaluated the potential clinical efficacy of panobacumab
in the treatment of nosocomial pneumonia. We per-
formed a post-hoc analysis of a multicenter phase IIa
trial (NCT00851435) designed to prospectively evaluate
the safety and pharmacokinetics of panobacumab. Patients
treated with panobacumab (n=17), including 13 patients re-
ceiving the full treatment (three doses of 1.2 mg/kg), were
compared to 14 patients who did not receive the antibody.
Overall, the 17 patients receiving panobacumab were more
ill. They were an average of 72 years old [interquartile range
(IQR): 64–79] versus an average of 50 years old (IQR: 30–73)
(p=0.024) and had Acute Physiology and Chronic Health
Evaluation II (APACHE II) scores of 17 (IQR: 16–22) versus
15 (IQR: 10–19) (p=0.043). Adjunctive immunotherapy re-
sulted in an improved clinical outcome in the group receiving
the full three-course panobacumab treatment, with a resolution
rate of 85 % (11/13) versus 64 % (9/14) (p=0.048). The
Kaplan–Meier survival curve showed a statistically significant-
ly shorter time to clinical resolution in this group of patients
(8.0 [IQR: 7.0–11.5] versus 18.5 [IQR: 8–30] days in those
who did not receive the antibody; p=0.004). Panobacumab
adjunctive immunotherapy may improve clinical outcome in a
shorter time if patients receive the full treatment (three doses).
These preliminary results suggest that passive immunotherapy
targeting LPS may be a complementary strategy for the treat-
ment of nosocomial O11 P. aeruginosa pneumonia.
Introduction
Pseudomonas aeruginosa is a recalcitrant, opportunistic
Gram-negative bacteria responsible for most nosocomial in-
fections of critically ill patients [1–3]. The development of
multidrug resistance makes the treatment of infections caused
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by this pathogen challenging [4, 5] and accounts for the
persistently high mortality rates observed in recent surveys
[6, 7], despite aggressive supportive management [8, 9]. The
number of new antimicrobials under clinical development
remains extremely limited, and their introduction to the mar-
ket is disappointingly slow [10], highlighting the urgency for
innovative approaches to be developed for the management of
multidrug-resistant infections [11, 12].
Adjunctive passive immunotherapy specifically targeted at
microbial products could be a promising strategy in overcom-
ing this problem. Historically, passive immunotherapy using
anti-sera was successfully carried out before the antibiotic era
for the management of devastating infectious diseases, such as
rabies and diphtheria [13]. The administration of intravenous
immunoglobulins as prophylaxis or as combination therapy
with antibiotics has shown promising results in treating sepsis
[14, 15]. The development of monoclonal antibodies (MAbs)
has improved antibody-based therapies by targeting specific
virulence factors on respective pathogens. However, adjunc-
tive immunotherapy targeted at host response mediators has,
so far, failed [16]. Therapies combining antimicrobials with
MAbs targeted at bacterial targets may potentially result in a
more rapid resolution of infections, resulting in reductions in
sepsis-related morbidity and mortality [17].
The membrane-bound virulence factor lipopolysaccharide
(LPS), expressed by all Gram-negative bacteria like
P. aeruginosa, elicits an immunoglobulin M (IgM)-mediated
antibody response that takes several days to fully develop, and
this delay may increase the risk of death in severe infections
[18]. Human monoclonal antibodies directed against
P. aeruginosa LPS have demonstrated protection in various
settings [19–21]. Panobacumab is a fully human monoclonal
antibody of the IgM/κ isotype directed against the LPS O-
polysaccharide moiety of P. aeruginosa O11 [22, 23].
P. aeruginosa international antigenic scheme serotypes O11
and O6 have been reported to be the most prevalent serotypes
among epidemiological studies [24, 25]. Strains exhibiting
exotoxin U, a potential virulence factor, were frequently
serotyped as O11 [25, 26]. In an experimental model of
pneumonia, serotype O11 was found to be associated with
increased lung injury [27]. These epidemiological data were
confirmed by a recent retrospective cohort study on 123
patients with nosocomial P. aeruginosa pneumonia, in which
O6 (29 %) and O11 (23 %) were the most prevalent serotypes
[28]. In this study, serotype O11was associated with increased
persisting pneumonia and decreased clinical resolution com-
pared to other serotypes. Preliminary data from an open phase
IIa study demonstrated the safety of panobacumab in critically
ill patients presenting with P. aeruginosa O11 nosocomial
pneumonia [29]. We performed a post-hoc analysis of this
study to evaluate the potential clinical efficacy of
panobacumab in the treatment of P. aeruginosa O11 nosoco-
mial pneumonia. The 17 patients that received panobacumab
were compared to a group of 14 patients screened in the study
that did not receive immunotherapy.
Patients and methods
Study population
We performed a post-hoc analysis of the multicenter, open
pilot phase IIa clinical trial (NCT00851435) which prospec-
tively evaluated the safety and pharmacokinetics of at least
one dose of 1.2 mg/kg panobacumab, a fully human mono-
clonal anti-LPS IgM, given every 72 h in 17 patients with
microbiologically documented [bronchoalveolar lavage
(BAL), mini-BAL] serotype O11 P. aeruginosa pneumonia
[29]. Definitions and detailed inclusion/exclusion criteria are
described elsewhere [29]. These patients (intent-to-treat group)
and those receiving the full three-dose treatment (per-protocol
group) were compared to a group consisting of patients who
fulfilled all the inclusion and exclusion criteria of the phase IIa
study but who could not receive panobacumab (not treated
with panobacumab group) (Fig. 1) for the following reasons:
(i) treatment refusal (n=3); (ii) physicians refused to give the
treatment (n=3); (iii) patients were screened after the end of the
trial (n=3); (iv) delayed serotyping results (n=2); or (iv) un-
known reasons (n=3).
Data collection
In addition to demographics (age, gender), the general condi-
tion of the patients was evaluated using the Acute Physiology
and Chronic Health Evaluation II (APACHE II) score system
[30]. Organ dysfunction was evaluated using the Sequential
Organ Failure Assessment (SOFA) score [31]. The severity of
pneumonia was assessed using the Clinical Pulmonary Infec-
tion Score (CPIS) [32].
Clinical endpoints
The clinical endpoints were as follows: (i) survival defined as
survival by day 30; (ii) clinical resolution was defined as no
persisting symptoms or complications attributable to the pneu-
monia with a return to normal values of all four of the
following: core body temperature (<38.3 °C), peripheral
blood leucocyte count (<10 × 103/mm3), PaO2/FIO2 ratio
(>25 kPa), and no or minimal growth of bacteria similar to
those isolated frommini-BAL samples in quantitative cultures
of endotracheal aspirates; (iii) time to clinical resolution was
defined as free of pneumonia and recurrence (relapse caused
by the same pathogen) at day 30 post-treatment; (iv) recur-
rence was defined as resolution of all clinical signs of pneu-
monia, including infiltrates, with a subsequent return of
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clinical signs and a diagnostic culture; (v) death was scored as
a non-resolved infection.
Statistical analysis
Statistical analyses compared patients that received at
least one dose or three doses of panobacumab to control
patients. Continuous variables are presented as median
[range, interquartile range (IQR)]. The characteristics of
patients and clinical outcomes were compared using
Fisher’s exact test and the Wilcoxon rank-sum test, as
indicated. Time to clinical resolution was analyzed
using the Kaplan–Meier survival model. All tests were
two-tailed, and statistical significance was established at
p-values <0.05.
Results
Demographics and severity of nosocomial pneumonia
The phase IIa clinical trial designed to test the safety, pharma-
cokinetics, and potential efficacy of panobacumab adjunctive
therapy screened 146 P. aeruginosa microbiologically docu-
mented nosocomial pneumonia cases. Thirty-one patients
were diagnosed with O11 serotype P. aeruginosa infections.
Among these, 17 fulfilled the inclusion criteria (intent-to-treat
group): four patients received only one dose and 13 patients
received the planned three doses of panobacumab (per-
protocol group). Fourteen patients suffering from nosocomial
pneumonia caused by P. aeruginosa O11 but who did not
receive panobacumab were used as untreated controls (Fig. 1).
The patient characteristics are summarized in Table 1.
Compared to untreated patients, patients that received
panobacumab presented with more severe forms of disease.
These patients were older (72 [IQR: 64–79] versus 50 [IQR:
30–73] years on average; p=0.024) and had higher APACHE
II scores (17 [IQR: 16–22) versus 15 [IQR: 10–19]; p=0.043).
The severity of pneumonia and the characteristics of antibiotic
treatment were comparable among treated and untreated
patients.
Outcome
The mortality rates were not statistically significant
between groups. A total of six patients died, including
three receiving only one dose of panobacumab. One
patient died 3 days after the first doses from a gastro-
intestinal hemorrhage before receiving the second dose.
Adjunctive treatment was stopped in a different patient
after the first dose following worsening of preexisting
cholestasis, who also presented with neutropenia and
gastrointestinal bleeding (he died on day 17 from mul-
tiple organ failure). In a third patient, cardiac arrest
followed by increased prothrombin time (possibly re-
lated to panobacumab treatment) precluded further
panobacumab administration. This patient died on day
17 after a second cardiac arrest. Three patients who did
not receive adjunctive treatment died on days 8, 10,
and 16, respectively, from colitis-related septic shock,
pneumonia-related multiple organ failure, and indeter-
minate causes, respectively.
Effect of adjunctive passive immunotherapy
When untreated patients were compared to patients that
received≥1 dose of panobacumab (intent-to-treat group),
there was no significant differences in clinical outcome,
with a shorter time to clinical resolution of pneumonia
and more disease-free days (Table 2). Differences were
statistically significant when untreated patients were
compared to patients that received the full planned treat-
ment (three doses of panobacumab). Specifically, time to
clinical resolution was 8.0 days (IQR: 7–12) versus
18.5 days (IQR: 8–30) (p=0.004), clinical resolution of
Fig. 1 Flow chart of patients
included in the post-hoc analysis
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pneumonia at day 30 was 85 % (11/13) in patients
receiving three doses of panobacumab versus 64 %
(9/14) in untreated patients (p=0.048), and disease-free
days were 22 (IQR: 18.5–23) versus 12.5 (IQR: 0–22)
(p=0.028). Kaplan–Meier survival curve analysis showed
a statistically significantly shorter time to clinical resolu-
tion in patients receiving three doses of panobacumab
(8.0 [IQR: 7.0–11.5] versus 18.5 [IQR: 8–30] days;
p=0.005) (Fig. 2). Two out of 13 patients receiving three
doses of panobacumab versus 1/14 untreated patients
developed recurrent pneumonia within 30 days (not sta-
tistically different).
Discussion
This manuscript describes a proof-of-concept analysis de-
scribing the administration of passive adjunctive immunother-
apy of a humanmonoclonal antibody that specifically targeted
Table 1 Characteristics of the patients presenting with Pseudomonas aeruginosa O11 nosocomial pneumonia
All patients
(n=31)
Not treated with
panobacumab
(n=14)
Panobacumab
“intent-to-treat”,≥1
dose (n=17)
Panobacumab
“per-protocol”,
three doses (n=13)
p-Values: not treated
vs.≥1 dose, not treated
vs. three doses
Age (years), median (IQR) 66 (42–77) 50 (30–73) 72 (64–79) 71 (61–79) 0.024, NS
Male/female (%) 70/30 57/43 82/18 77/23 0.039, NS
Initial antibiotic treatment, n (%) NS, NS
Bi-therapy 11 (78.6 %) 10 (58.8 %) 8 (61.5 %)
Beta-lactam + aminoglycoside 11 2 2
Beta-lactam + quinolone 6 5
Beta-lactam + colistin 2 1
Monotherapy 3(21.4 %) 7(41.6 %) 5(38.5 %)
Beta-lactam 3 6 4
Quinolone 1 1
Inadequately treated with antibiotics, n (%) 4 (13.3 %) 1 (7.1 %) 3 (17.6 %) 2 (15.5 %) NS, NS
APACHE II score, median (IQR) 17 (14–20) 15 (10–19) 17 (16–22) 17 (15.5–23.5) 0.043, 0.048
CPIS, median (IQR) 8.0 (7.0–9.0) 8.0 (5.8–9.3) 9.0 (7.5–9.5) 9 (8.0–9.5) NS, NS
SOFA score, median (IQR) 6.0 (4.5–9.0) 7.0 (4.8–9.3) 6.0 (4.0–7.0) 5.5 (3.8–7.8) NS, NS
Length of hospital stay (days) before
pneumonia, median (IQR)
15.0 (7.0–29) 14.5 (4.8–32) 15 (8.5–32) 17 (8.5–36) NS, NS
Length of ICU stay (days) before
pneumonia, (IQR)
9.0 (6.0–19.5) 6.5 (3.8–24) 10.5 (6.8–17.8) 13 (7.0–19.3) NS, NS
IQR interquartile range, NS not significant, CPIS Clinical Pulmonary Infection Score, APACHE II Acute Physiology and Chronic Health Evaluation II,
SOFA Sequential Organ Failure Assessment
Table 2 Clinical outcomes
All patients
(n=31)
Not treated with
panobacumab
(n=14)
Panobacumab
“intent-to-treat”,≥1
dose (n=17)
Panobacumab
“per-protocol”,
three doses (n=13)
p-Values: not treated
vs.≥1 dose, not treated
vs. three doses
Time (days) to clinical resolution
of pneumonia, median (IQR)
12.0 (8.0–30) 18.5 (8.0–30) 10.0 (7.0–23) 8.0 (7.0–12) NS, 0.004
Clinical resolution of pneumonia, n (%) 20 (65 %) 9 (64 %) 11 (65 %) 11 (85 %) NS, 0.048
Disease-free days 18 (0–22) 12.5 (0–22) 20 (7.5–23) 22 (18.5–23) NS, 0.028
Relapse within 30 days, n (%) 4 (13 %) 1 (7 %) 3 (18 %) 2 (15 %) NS, NS
Survival at day 30, n (%) 25 (81 %) 11 (79 %) 14 (83 %) 13 (100 %) NS, NS
IQR interquartile range
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the P. aeruginosa O11 LPS O-polysaccharide moiety. This
form of immunotherapy may have improved the clinical out-
come of patients presenting with nosocomial pneumonia.
Differences were statistically significant only between
patients that received three doses of panobacumab. In
these patients, an 85 % success rate and a more rapid
clinical resolution was achieved, despite these patients
presenting with more severe infections and underlying
conditions.
Three patients that received only one dose of panobacumab
adjunctive immunotherapy died. One died early from septic
shock related to the infection and two patients that were
excluded by the independent phase IIa panobacumab clinical
trial safety committee died later. This may be viewed as a
limitation, but it should be pointed out that the full effect of
adjunctive immunotherapy targeted at a virulence factor may
not be achieved immediately and that repetitive doses may be
required to achieve a clinical effect.
These results are consistent with previous in vitro and
in vivo data obtained with panobacumab. The diffusion of
panobacumab from blood into the alveolar spaces may have
contributed to its efficacy [29]. Moreover, observed relapses
at day 30 may be explained by the disappearance of
panobacumab from the blood [29] at this time.
Conclusions regarding the clinical efficacy of panobacumab
in the treatment of nosocomial P. aeruginosa O11 infections
should be made with caution, since this post-hoc analysis
consisted of a limited number of patients. Nevertheless, such
preliminary results are encouraging and may justify a large
prospective randomized clinical trial in critically ill patients
presenting with P. aeruginosa nosocomial infections.
In summary, these preliminary results suggested that the
full course of panobacumab adjunctive immunotherapy (three
doses) targeting serotype-specific LPS of P. aeruginosa O11
may have improved the clinical outcome of patients present-
ing with nosocomial pneumonia.
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Fig. 2 Kaplan–Meier clinical resolution curve of patients receiving
panobacumab versus untreated patients. a Patients with nosocomial
Pseudomonas aeruginosa O11 pneumonia receiving≥1 dose of
panobacumab (blue: intent-to-treat group; n=17) versus untreated pa-
tients (red: n=14). p-Value (log-rank test): 0.3008. b Patients with noso-
comial P. aeruginosa O11 pneumonia receiving the full treatment (three
doses) of panobacumab (blue: per-protocol group; n=13) versus untreat-
ed patients (red: n=14). p-Value (log-rank test): 0.0045
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